

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number
WO 02/06288 A1

(51) International Patent Classification⁷: **C07D 495/04**, 513/04, 487/04, A61K 31/55, A61P 25/00 // (C07D 495/04, 333:00, 223:00) (C07D 513/04, 277:00, 223:00) (C07D 487/04, 239:00, 223:00)

(21) International Application Number: PCT/EP01/08186

(22) International Filing Date: 16 July 2001 (16.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00115450.9 18 July 2000 (18.07.2000) EP

(71) Applicant: **F.HOFFMANN-LA ROCHE AG [CH/CH]**; Grenzacherstrasse 124, CH-4070 Basle (CH).

(72) Inventors: **BINGGELI, Alfred**; Im Kugelfang 50, CH-4102 Binningen (CH). **MAERKI, Hans-Peter**; Seltisbergerstrasse 75, CH-4059 Basel (CH). **MUTEL, Vincent**; 15, place des Maréchaux, F-68100 Mulhouse (FR). **WOSTL, Wolfgang**; Im Strick 2, 79639 Grenzach-Wyhlen (DE). **WILHELM, Maurice**; 11, chemin du Luegner, F-68790 Morschwiller la Bas (FR).

(74) Agent: **WAECHTER, Dieter**; Grenzacherstrasse 124, CH-4070 Basle (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDRO-HETEROCYCLOAZEPINYL PYRIMIDINE DERIVATIVES




(I)

(57) Abstract: The invention relates to compounds of the general formula (I) wherein HET and R¹ to R¹² have the significances as defined in the specification, as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of formula (I) are group (I) mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.

WO 02/06288 A1

Tetrahydro-heterocycloazepinyl pyrimidine derivatives


The present invention is concerned with nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives of the general formula




I

wherein



- 5 R¹ signifies oxygen, hydroxy, lower alkoxy or 2,2,2-trifluoroethoxy;
- R² signifies nitro or cyano;
- R³ signifies hydrogen, lower alkyl, oxygen, lower alkoxy, amino, lower alkyl-amino or hydroxy-lower alkyl-amino;
- R⁴ signifies hydrogen, lower alkyl, lower alkenyl,
10 or is absent, if the adjacent nitrogen atom already is the origin of three
 bonds as -N= or =N-;
- R⁵, R⁶, R⁹ and R¹⁰ signify, independently from each other, hydrogen or lower alkyl;




- 2 -



or



or



- 1 R⁷, R⁸, R¹¹ or R¹² signify, independently from each other, hydrogen, lower alkyl, or hydroxy;
- 2 R¹³ and R¹⁴ signify, independently from each other, hydrogen or lower alkyl;
- 3 R¹⁵ and R¹⁶ signify, independently from each other, hydrogen or lower alkyl;
- 4 R¹⁷ signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;
- 5 R¹⁸ signifies hydrogen or hydroxy;
- 6 R¹⁹ signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;
- 7 V signifies NH, S or O; and
- 8 the dotted line may be a bond,

as well as with their pharmaceutically acceptable salts in their racemic and optically active form.

It has surprisingly been found that the compounds of general formula I are antagonists at metabotropic glutamate receptors.

- 3 -

In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter sent out by a neuron, with another neuroreceptor.

L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes. The glutamate-dependent stimulus receptors are divided into two main groups. The first main group forms ligand-controlled ion channels. The metabotropic glutamate receptors (mGluR) belong to the second main group and, furthermore, belong to the family of G-protein-coupled receptors.

At present, eight different members of these mGluRs are known and some of these even have sub-types. On the basis of structural parameters, the different second messenger 10 signaling pathways and their different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups:

mGluR1 and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR6, mGluR7 and mGluR8 belong to group III.

Ligands of metabotropic glutamate receptors belonging to the first group can be used 15 for the treatment or prevention of acute and/or chronic neurological disorders such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.

Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head 20 injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate 25 addiction, psychoses, anxiety, vomiting, dyskinesia and depression.

Objects of the present invention are compounds of formula I and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of the compounds in accordance with the invention in 30 the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments. Furthermore, the use of radiolabeled mGluR1

- 4 -

receptor antagonists of formula I in a binding assay is also an object of the present invention.

Preferred compounds of formula I in the scope of the present invention are those, in which R² is NO₂.

5 Further preferred are compounds of formula I in the scope of the present invention, wherein

R¹ is =O or lower alkoxy and

HET represents a thiophene group.

The following are examples of such compounds:

10 [rac]-6-(4-Hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one,

15 6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine, or

3-Ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one.

Also preferred are compounds of formula I in the scope of the present invention, wherein

20 R¹ is =O or lower alkoxy, and

HET represents a thiazole group.

The following are examples of such compounds:

2-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

25 6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine,

3-Ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

30 6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one, or

- 5 -

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one.

Further preferred compounds of formula I in the scope of the present invention are those, in which

- 5 R¹ is hydroxy and {
HET represents a pyrimidine group.

The following are examples of such compounds:

7-(6-Hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol, or

- 10 2-Methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol.


The term "lower alkyl" used in the present description denotes straight-chain or branched saturated hydrocarbon residues with 1-7 carbon atoms, preferably with 1-4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl and the like.

- 15 The term "lower alkenyl" used in the present description denotes straight-chain or branched unsaturated hydrocarbon residues with 2-7 carbon atoms, preferably with 2-4 carbon atoms.

The term "lower alkoxy" denotes a lower alkyl residue in the sense of the foregoing definition bonded via an oxygen atom.


- 20 The compounds of general formula I and their pharmaceutically acceptable salts can be manufactured by

- a) reacting a compound of the formula




with a compound of formula

- 6 -




to a compound of formula




wherein R³ and R⁵ to R¹² have the significance given above.

5 b) reacting a compound of formula




to a compound of formula




or to a compound of formula

- 7 -




wherein R², R³ and R⁵ to R¹² have the significance given above and R signifies hydrogen or lower alkyl, or

c) reacting a compound of formula




5

with a compound of formula



to a compound of formula



10

wherein the substituents have the significance given above,

and, if desired,

converting a functional group in a compound of formula I into another functional group and, if desired,


converting a compound of formula I into a pharmaceutically acceptable salt.

- 8 -

In the following schemes I to VII and in Examples 1 - 10 the reaction steps and reaction variants a) - c) are described in more detail.

Chloro-methoxy-nitro pyrimidines VII (Scheme I) are known [e.g. 6-chloro-4-methoxy-2-methyl-5-nitro-pyrimidine: Helv. (1958), 41, 1806]. Treatment of the 2-alkyl 6-chloro-4-methoxy-5-nitro-pyrimidines VII with hydrobromic acid in acetic acid preferentially at temperatures between 0 °C and 60 °C gives the 2-alkyl-6-bromo-5-nitro-3H-pyrimidin-4-ones III (Scheme I).


Scheme I



10 The 2-alkyl-6-bromo-5-nitro-3H-pyrimidin-4-ones III react with optionally substituted secondary amines IV in the presence of a base like triethylamine in solvents like N,N-dimethylformamide, dimethylsulfoxide, acetone, methyl-ethylketone or tetrahydrofuran at temperatures between 0 °C and 100 °C to the tertiary amines I-1 (Scheme II).


15

Scheme II



Bis(methylthio)-acrylates VIII react with optionally substituted secondary amines IV in the presence of bases like potassium carbonate and/or triethylamine in solvents like ethanol, methanol, acetone or methyl-ethylketone at temperatures between room temperature and 100 °C to adducts V, which can be formed as Z-isomer, as mixture of E and Z isomers or as E isomer (Scheme III). Adducts V can be reacted with amidines, urea or thiourea derivatives VI either in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene in N,N-dimethylformamide or dimethylsulfoxide at temperatures between 70 °C and 140 °C or in the presence of sodium ethylate in ethanol preferentially at reflux thus yielding pyrimidineoles I-2 or pyrimidinones I-3.

- 9 -

Scheme III


Alkylation of adducts I-2 with R² being a cyano or a nitro group (Scheme III) using optionally substituted alkyl halides, tosylates, mesylates or trifluoro-methanesulfonates in solvents like ethanol, methanol, dichloromethane, chloroform, N,N-dimethylformamide, dimethylsulfoxide, acetone, methyl-ethylketone or tetrahydrofuran in the presence of a base like alkali carbonates, e.g. sodium, potassium or cesium carbonate, tertiary amines like triethylamine or ethyl-diisopropylamine, alkali methyl hydrides, like sodium or potassium hydride, or phase transfer catalysts like benzyl-trimethylammonium chloride in the presence of solid or concentrated aqueous sodium hydroxide gives variable mixtures of N- and/ or O-alkylated products I-3 and I-4.

Azepines IV-1 condensed to a heteroaromatic 5-membered ring bearing two heteroatoms can be prepared from bromoazepinones IX (Scheme IV) as e.g. 4-bromo-5-

- 10 -

oxo-azepane-1-carboxylic acid tert.-butyl ester (prepared from 5-bromo-azepan-4-one hydrobromide (1:1) [Ger. Offen. (1989), DE 3820775] with di-tert.-butyldicarbonate in dioxane/aq. sodium hydrogen carbonate solution at room temperature) by reaction with an amide, a thioamide, an urea or a thiourea compound in a solvent like ethanol, dioxane or acetonitrile in the presence of a base like sodium ethylate or triethylamine at temperatures between room temperature and 120 °C followed by removal of the tert.-butoxy carbonyl function with acid, e.g. with hydrogen chloride (aqueous, 37%) in methanol at temperatures between room temperature and 80 °C.

Scheme IV



10


IV-1

Azepines **IV-2** condensed to a heteroaromatic 6-membered ring bearing two heteroatoms can be prepared from alkoxy carbonyl-azepinones **XII** as e.g. 4-ethoxy carbonyl-5-oxo-azepane-1-carboxylic acid tert.-butyl ester [Synthetic Communications 22 (1992), 1249-1258] (Scheme V) by condensation with an amidine **XIII** in a solvent like ethanol, dioxane or N,N-dimethylformamide in the presence of a base like sodium ethoxide or potassium tert.-butylate at temperatures between 40 °C and 110 °C. The primarily formed compounds **XIVa** can be further modified by transformation of the hydroxy function into a leaving group, e.g. a trifluorosulfonyloxy function with trifluorosulfonic acid anhydride and a base like triethylamine in an inert solvent like dichloromethane at temperatures between -40 °C and 60 °C, thus giving compounds **XIVb**. The trifluorosulfonyloxy function in compounds **XIVb** can then be replaced by a hydrazine moiety by reacting it with hydrazine in a solvent like ethanol preferentially at reflux giving

- 11 -

- compounds XIVc. Hydrazino-compounds XIVc can be transformed by silver oxide in ethanol at reflux into the compounds XIVd, a sequence as described in [Bull. Chem. Soc. Jap. (1971), 44(1), 153-8]. Removal of the tert.-butoxy carbonyl function in compounds XIVa or XIVd with acid, e.g. with hydrogen chloride (aqueous, 37%) in methanol at 5 temperatures between room temperature and 80 °C gives then the azepines IV-2.

Scheme V



- 5,6,7,8-Tetrahydro-4H-thieno[2,3-d]azepines IV-3 and IV-5 with or without a hydroxy function at the carbon attached to the thieno moiety are known [J. Heterocyclic Chem. 22, 1011 (1985)]. Precursor acid chlorides XV bearing preferentially a tosyloxy protective function at the azepine secondary nitrogen function are cyclized in an inert solvent like 1,2-dichloroethane, dichloromethane or nitrobenzene in the presence of a Lewis acid catalyst like aluminium trichloride, tin tetrachloride or phosphorous pentachloride at temperatures between -40 °C and 80 °C to yield the protected ketones 10 XVII. Keto thieno[2,3-d]azepines IV-4 are then prepared by cleavage of N-tosyl function with hydrobromic acid in the presence of a scavenger reagent like phenol in a solvent like ethyl acetate at room temperature, whereas hydroxy thieno[2,3-d]azepines IV-3 can be 15 XVI.

- 12 -


obtained by simultaneous reduction of the keton function and removal of the N-tosyl protective function by treatment with sodium bis(methoxyethoxy)aluminium-hydride in toluene at reflux. The hydroxy thieno[2,3-d]azepines IV-3 can be further reduced to 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepines IV-5 with stannous chloride in acetic acid in
5 the presence of hydrochloric acid at temperatures between room temperature and 100 °C.

5,6,7,8-Tetrahydro-4H-thieno[3,4-d]azepines IV-6 isomeric to 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepines IV-5 can be prepared from 2-thiophen-3-yl-ethylamine derivatives XVII [Eur. Pat. Appl. (1988), EP 274324 A1] in an analogous sequence as described for the thieno[2,3-d]azepines outlined in detail in Scheme VI.

10

Scheme VI

- 13 -




A labeled compound, for example 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile, is needed for the binding assay for the characterization of mGluR 1 antagonistic properties and can be prepared according to synthesis schemes I – III starting from a labeled amine as the 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine XXI which can be prepared as outlined in

- 14 -

Scheme VII. The 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone XIX can be obtained by reaction of the 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XVIII [J. Heterocycl. Chem. (1971), 8(5), 779-83] with N-bromosuccinimide in carbon tetrachloride in the presence of a radical initiator like dibenzoylperoxide or 1,1'-azobis(cyclohexanecarbonitrile) preferentially at reflux. Hydrogenation of the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone XIX with tritium gas using a palladium or platinum catalyst in solvents methanol, ethanol or an ether like tetrahydrofuran preferentially in the presence of a base like triethylamine gives the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XX which can be converted into the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone XXI with conc. aq. hydrochloric acid in methanol.

Scheme VII



The pharmaceutically acceptable salts can be manufactured readily according to methods known per se and taking into consideration the nature of the compound to be converted into a salt. Inorganic or organic acids such as, for example, hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid, phosphoric acid or citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like are suitable for the formation of pharmaceutically acceptable salts of basic compounds of formula I. Compounds which contain the alkali metals or alkaline earth metals, for example sodium, potassium, calcium, magnesium or the like, basic amines or basic amino acids are suitable for the formation of pharmaceutically acceptable salts of acidic compounds of formula I.

- 15 -

The compounds of formula I and their pharmaceutically acceptable salts are, as already mentioned above, metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, 5 cognitive disorders, memory deficits and psychosis. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused 10 by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.

The compounds of the present invention are group I mGluR antagonists and were tested using the following method:

15 Binding assay for the characterization of mGluR 1 antagonistic properties

Binding assay with tritiated 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile: HEK 293 cells were transiently transfected with the rat mGluR1a receptor. The cells were collected and washed 3 times with PBS. The cell pellets were frozen at -80 °C. Membranes were prepared from 20 HEK 293 cells transfected with the rat mGluR1a receptor and used in the binding experiments at 10 µg proteins per assay after resuspension in a HEPES NaOH 20mM, pH=7.4 binding buffer. 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydrobenzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile (S.A 33.4Ci/mmol) was used at 3 nM final concentration. The incubation with variable concentrations of potential 25 inhibitors was performed for 1 hour at room temperature, the incubate was then filtered onto GF/B glass fiber filter preincubated 1 hour in PEI 0,1% and washed 3 times with 1ml of cold binding buffer. The radioactivity retained on the unifilter 96 was counted using a Topcount β counter. After correction for non specific binding the data were normalized and the IC₅₀ value calculated using a 4 parameters logistic equation which was fitted to the 30 inhibition curve.

Preferred compounds have an IC₅₀ range of 0,001 – 50,00 µM (B-IC₅₀).

- 16 -

In the table below are shown some specific activity data of preferred compounds:

	Example No.	B-IC ₅₀ (μM)
2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one	1	30
6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine	2	4.2
3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one	2	2.1
6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one	3	49
6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one	4	6
2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one	6	43
2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one	9	1.9
6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine	10	0.44
3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one	10	0.069

The compounds of formula I and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for

- 17 -

example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as
5 alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula I, but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.

In addition, the pharmaceutical preparations can contain preservatives, solubilizers,
10 stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

As mentioned earlier, medicaments containing a compound of formula I or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an
15 object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula I or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.

20 The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and
25 700 mg per day.

Finally, as mentioned earlier, the use of compounds of formula I and of pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind, is also an object of the invention.

- 18 -

Example 1

2-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one

a) 6-Bromo-2-methyl-5-nitro-3H-pyrimidin-4-one

5 56.6 ml (503 mmol) of hydrobromic acid solution (48% in water) were added dropwise to a solution of 20.5 g (101 mmol) of the 2-methyl-4-methoxy-5-nitro-6-chloro-pyrimidine [Helv. (1958), 41, 1806] in 450 ml of acetic acid and the reaction mixture was stirred at room temperature for 44 hours. It was then evaporated under reduced pressure and the residue formed poured into 500 ml of an ice/water mixture and extracted 3 times with 500
10 ml of dichloromethane. The combined dichloromethane phases were washed with 100 ml of water and evaporated under reduced pressure. There were thus obtained 16.3 g (69.6 mmol, yield 69%) of the 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one as light yellow solid, which was used without further purification.

b) 2-Methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine

15 The title compound was prepared by the following reaction sequence: i) treatment of the 5-bromo-azepan-4-one hydrobromide (1:1) [Ger. Offen. (1989), DE 3820775] with di-t-butyl dicarbonate in dioxane/aq. sodium hydrogen carbonate solution to yield the 4-bromo-5-oxo-azepane-1-carboxylic acid tert-butyl ester; ii) treatment of the 4-bromo-5-oxo-azepane-1-carboxylic acid tert-butyl ester with thioacetamide in ethanol in the
20 presence of triethylamine at reflux to give the 2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester; iii) conversion of the 2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester into the 2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine by removal of the tert-butyloxycarbonyl function with hydrogen chloride (aqueous, 37%) in methanol at room temperature.

25 c) 2-Methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one

A suspension of 0.234 g (1.00 mmol) of the 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one, 0.205 g (1.00 mmol) of the 2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine hydrochloride and 0.304 g (2.20 mmol) of potassium carbonate in 2.0 ml of N,N-dimethylformamide was stirred at room temperature for 60 hours. The reaction mixture was then poured into 50 ml of an ice/water mixture and the crystals formed collected by

- 19 -

filtration. Thus, a first crop of the 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one was obtained. The mother liquor was then evaporated and the residue chromatographed on silica gel using a 9:1 v/v mixture of dichloromethane and methanol as eluent giving a second crop of the 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one, in total 0.252 g (0.785 mmol, yield 78.5%) as light yellow solid; m.p. >200 °C; MS: [M+H]⁺ = 322.

Example 2

6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine
and
3-Ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one

A suspension of 0.120 g (0.373 mmol) of 2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one (example 1), of 0.070 g (0.45 mmol) of the ethyl iodide and of 0.077 g (0.56 mmol) of potassium carbonate in 1.0 ml of N,N-dimethylformamide was stirred at room temperature for 4 hours. The reaction mixture was then poured into 50 ml of an ice/water mixture and extracted 3 times with 50 ml of ethylacetate. The combined ethylacetate phases were dried over magnesium sulfate and evaporated under reduced pressure. The residue formed was then chromatographed on silica gel using a 95:5 v/v mixture of dichloromethane and methanol as eluent giving in a first fraction 0.025 g (0.072 mmol, yield 19%) of the 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine as yellow amorphous solid; MS: [M+H]⁺ = 350.

The second fraction provided 0.081 g (0.23 mmol, yield 62%) of the 3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one as yellow solid after crystallization from ether; m.p. 164.2-166.8 °C; MS: [M+H]⁺ = 350.

Example 3

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one

- 20 -

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one as prepared in example 1a was treated with 2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine [Ger. Offen. (1989), DE 3820775] in N,N-dimethylformamide in the presence of potassium carbonate at 110 °C to yield the title compound as yellow solid; m.p. >200 °C; MS: $[M+H]^+$ = 323.

Example 4

6-(2-Amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one

In analogy to the procedure described in example 2 the 6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one (example 3) was treated with the ethyl iodide in N,N-dimethylformamide in the presence of potassium carbonate at room temperature to yield the title compound as yellow solid; m.p. >200 °C; MS: $[M+H]^+$ = 351.

Example 5

15 7-(6-Hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the 2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol (prepared from the corresponding N-benzyl derivative [Bull. Chem. Soc. Jap. (1971), 44(1), 153-8] by catalytic hydrogenation with palladium on charcoal) in N,N-dimethylformamide in the presence of triethylamine at room temperature to yield the title compound as yellow solid; m.p. >200 °C; MS: $[M+H]^+$ = 333.

Example 6

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one

25 a) 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine

The title compound was prepared by the following reaction sequence: i) treatment of 4-bromo-5-oxo-azepane-1-carboxylic acid tert-butyl ester (example 1 b) with phosphorous pentasulfide, formamide and triethylamine in dioxane at reflux to yield 4,5,7,8-tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester; ii) conversion of 4,5,7,8-

- 21 -

tetrahydro-thiazolo[4,5-d]azepine-6-carboxylic acid tert-butyl ester into 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine by removal of the tert-butyloxycarbonyl function with hydrogen chloride (aqueous, 37%) in methanol at room temperature.

b) 2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the 5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine in N,N-dimethylformamide in the presence of potassium carbonate at room temperature to yield the 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one as yellow amorphous solid; MS: [M-H]⁻ = 306.

Example 7

2-Methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepine trihydrochloride [Bull. Chem. Soc. Jap. (1971), 44(1), 153-8] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as yellow solid; m.p. >200 °C; MS: [M-H]⁻ = 301.

Example 8

[rac]-6-(4-Hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one

In analogy to the procedure described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with the [rac]-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepin-4-ol [J. Heterocycl. Chem. (1985), 22(4), 1011-16] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as light yellow oil; MS: [M-H]⁻ = 321.

Example 9

2-Methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one

- 22 -

- According to the method described in example 1c 6-bromo-2-methyl-5-nitro-3H-pyrimidin-4-one (example 1a) was treated with 5,6,7,8-tetrahydro-4H-thieno-[2,3-d]azépine [J. Heterocycl. Chem. (1985), 22(4), 1011-16] in N,N-dimethylformamide in the presence of N-ethyl-di-isopropylamine at room temperature to yield the title compound as
- 5 yellow solid; m.p. >200 °C; MS: $[M-H]^- = 305$.

Example 10

6-(6-Ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine

and

- 10 3-Ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one

In analogy to the procedure described in example 2 2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one (example 9) was treated with ethyl bromide in N,N-dimethylformamide in the presence of potassium carbonate at room

15 temperature to yield 6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine as light yellow amorphous solid; MS: $[M+H]^+ = 335$; and 3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one as yellow foam; MS: $[M+H]^+ = 335$.

Preparation of the labeled compound needed for the binding assay

- 20 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

a) 1,1,2-Tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine

The 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine was obtained by the following sequence:

- 25 i) reaction of the 1-(1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone [J. Heterocycl. Chem. (1971), 8(5), 779-83] with dibenzoylperoxide and N-bromosuccinimide in carbon tetrachloride at reflux yielded the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone;

- 23 -

ii) hydrogenation of the 1-(5-bromo-1,2-dihydro-benzo[d]azepin-3-yl)-ethanone with tritium using Pd/C in methanol in the presence of triethylamine yielded the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone;

iii) treatment of the 1-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-ethanone with conc. aq. hydrochloric acid in methanol gave the 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine.

b) E- and/or Z-2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester

A solution of 35 mg (0.16 mmol) of ethyl 2-cyano-3,3-bis(methylthio)acrylate, of 4.4 mg (0.024 mmol) of 1,1,2-tritritio-2,3,4,5-tetrahydro-1H-benzo[d]azepine hydrochloride, and of 10 mg (0.1 mmol) of triethylamine in 0.37 ml of ethanol was heated at reflux for 6.5 h. The reaction mixture was then evaporated and the residue chromatographed on 6 g Lichroprep silica gel Si-60 (25-40 μ m) using a 5:1 v/v mixture of toluene and ethyl acetate as eluent. Thus, 4.5 mg (0.014 mmol, yield 60%) of the *E*- and/or *Z*- 2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester was obtained.

c) 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

A solution of 4.4 mg (0.014 mmol) of *Z*- and/or *E*-2-cyano-3-methylsulfanyl-3-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-acrylic acid ethyl ester, of 3 mg (0.032 mmol) of acetamidine hydrochloride and of 6.6 mg (0.044 mmol) of 1,8-diazabicyclo[5.4.0]undec-7-ene in 1.0 ml of N,N-dimethylformamide was stirred at 100 °C for 2 hours. The reaction mixture was then partitioned between a 50:1 v/v mixture of dichloromethane and methanol and ice water acidified with about 2 ml 0.2 N hydrogen chloride. The organic phase was dried over anhydrous sodium sulfate. The crude product was chromatographed on 5 g Lichroprep silica gel Si-60 (25-40 μ m) using a 6:1 v/v mixture of toluene and methanol as eluent. There was thus obtained 2.2 mg (0.008 mmol, yield 57%) of 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile.

d) 1-Ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile

- 24 -

A suspension of 2.2 mg (0.008 mmol) of 2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile, of 16 mg (0.10 mmol) of ethyl iodide and of 4.3 mg (0.031 mmol) of potassium carbonate in 0.21 ml of N,N-dimethylformamide was stirred at room temperature for 3 h. The reaction mixture
5 was then partitioned between ethyl acetate and ice water acidified with about 1 ml 0.2 N hydrochloric acid. The organic phase was dried over anhydrous sodium sulfate. The thus obtained crude product was purified by chromatography on 5 g Lichroprep silica gel Si-60 (15-25 μ m) using a 50:1 v/v mixture of dichloromethane and methanol as eluent to yield
10 1.8 mg (0.0058 mmol, yield 73 %) of the 1-ethyl-2-methyl-6-oxo-4-(1,1,2-tritritio-1,2,4,5-tetrahydro-benzo[d]azepin-3-yl)-1,6-dihydro-pyrimidine-5-carbonitrile as colorless solid, MS: $[M(^3H_0)+H]^+$ = 309 (27%), MS: $[M(^3H_1)+H]^+$ = 311 (38%), MS: $[M(^3H_2)+H]^+$ = 313 (27%), MS: $[M(^3H_3)+H]^+$ = 315 (8%).

- 25 -

Example A

Tablets of the following composition are produced in a conventional manner:

	mg/Tablet
	100
5	Powdered lactose
	95
	White corn starch
	35
	Polyvinylpyrrolidone
	8
	Na carboxymethylstarch
	10
	Magnesium stearate
	2
10	Tablet weight 250

Example B

Tablets of the following composition are produced in a conventional manner:

	mg/Tablet
	200
15	Powdered lactose
	100
	White corn starch
	64
	Polyvinylpyrrolidone
	12
	Na carboxymethylstarch
	20
	Magnesium stearate
	4
20	Tablet weight 400

- 26 -

Example C

Capsules of the following composition are produced:

mg/Capsule

	Active ingredient	50
5	Crystalline lactose	60
	Microcrystalline cellulose	34
	Talc	5
	Magnesium stearate	1


Capsule fill weight 150

- 10 The active ingredient having a suitable particle size, the crystalline lactose and the microcrystalline cellulose are homogeneously mixed with one another, sieved and thereafter talc and magnesium stearate are admixed. The final mixture is filled into hard gelatine capsules of suitable size.

- 27 -



Claims

1. Compounds of the general formula





wherein

- 5 R^1 signifies oxygen, hydroxy, lower alkoxy or 2,2,2-trifluoroethoxy;
- R^2 signifies nitro or cyano;
- R^3 signifies hydrogen, lower alkyl, oxygen, lower alkoxy, amino, lower alkyl-amino or hydroxy-lower alkyl-amino;
- R^4 signifies hydrogen, lower alkyl, lower alkenyl,
- 10 or is absent, if the adjacent nitrogen atom already is the origin of three bonds as $-N=$ or $=N-$;
- R^5 , R^6 , R^9 and R^{10} signify, independently from each other, hydrogen or lower alkyl;




or





or



or

R^7 , R^8 , R^{11} or R^{12} signify, independently from each other, hydrogen, lower alkyl, or hydroxy;

R^{13} and R^{14} signify, independently from each other, hydrogen or lower alkyl;

R^{15} and R^{16} signify, independently from each other, hydrogen or lower alkyl;

5 R^{17} signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

R^{18} signifies hydrogen or hydroxy;

R^{19} signifies hydrogen, lower alkyl, lower alkoxy, hydroxy or amino;

 V signifies NH, S or O; and

the dotted line may be a bond,

10 as well as their pharmaceutically acceptable salts.

2. Compounds of formula I in accordance with claim 1, wherein R^2 is NO_2 , and pharmaceutically acceptable salts thereof.

3. Compounds of formula I in accordance with claims 1 and 2, wherein R^1 is $=O$ or lower alkoxy and HET represents a thiophene group, and pharmaceutically acceptable salts thereof.

15 4. Compounds of formula I in accordance with claim 3, which are

[rac]-6-(4-hydroxy-4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one,

6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine, or

5 3-ethyl-2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thieno[2,3-d]azepin-6-yl)-3H-pyrimidin-4-one.

5. Compounds of formula I in accordance with claims 1 and 2, wherein R¹ is =O or lower alkoxy and HET represents a thiazole group, and pharmaceutically acceptable salts thereof.

10 6. Compounds of formula I in accordance with claim 5, which are

2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

6-(6-ethoxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine,

15 3-ethyl-2-methyl-6-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-5-nitro-3H-pyrimidin-4-one,

6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-2-methyl-5-nitro-3H-pyrimidin-4-one,

20 6-(2-amino-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3-ethyl-2-methyl-5-nitro-3H-pyrimidin-4-one, or

2-methyl-5-nitro-6-(4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-3H-pyrimidin-4-one.

7. Compounds of formula I in accordance with claims 1 and 2, wherein R¹ is hydroxy and HET represents a pyrimidine group, and pharmaceutically acceptable salts thereof.

25 8. Compounds of formula I in accordance with claim 7, which are


7-(6-hydroxy-2-methyl-5-nitro-pyrimidin-4-yl)-2-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-ol, or

- 30 -

2-methyl-5-nitro-6-(5,6,8,9-tetrahydro-pyrimido[4,5-d]azepin-7-yl)-pyrimidin-4-ol.


9. A medicament comprising a compound of formula I according to any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients.
- 5 10. A medicament in accordance with claim 9 for the control or prevention of acute and/or chronic neurological disorders such as epilepsy, stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, 10 hypoglycaemia, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
- 15 11. Compounds of formula I in accordance with any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof for use in the control or prevention of illness.
12. The use of compounds of formula I in accordance with any one of claims 1 to 8 as well as pharmaceutically acceptable salts thereof for the manufacture of a medicament for the control or prevention of acute and/or chronic neurological disorders such as epilepsy, 20 stroke, chronic and acute pain, psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest, hypoglycaemia, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused 25 by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia and depression.
13. A process for the manufacture of compounds according to any one of claims 1 to 8 as well as of pharmaceutically acceptable salts thereof, which process comprises
- 30 a) reacting a compound of the formula

- 31 -




III

with a compound of formula



IV


to a compound of formula



5


wherein R³ and R⁵ to R¹² have the significance given above.

b) reacting a compound of formula




to a compound of formula

- 32 -




or to a compound of formula




wherein R², R³ and R⁵ to R¹² have the significance given above and R signifies
5 hydroxy or lower alkyl, or

c) reacting a compound of formula




with a compound of formula



10 to a compound of formula

- 33 -



wherein the substituents have the significance given above,

and, if desired,

converting a functional group in a compound of formula I into another functional group
5 and,

if desired,

converting a compound of formula I into a pharmaceutically acceptable salt.

14. Compounds of formula I in accordance with any one of claims 1 to 8, when
manufactured by a process in accordance with claim 13.

10 15. The invention as herein described.

INTERNATIONAL SEARCH REPORT

Inte - n Application No
PC1/EP 01/08186

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D495/04 C07D513/04 C07D487/04 A61K31/55 A61P25/00
 //((C07D495/04, 333:00, 223:00), (C07D513/04, 277:00, 223:00),
 (C07D487/04, 239:00, 223:00))

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 3 804 849 A (GRISS G ET AL) 16 April 1974 (1974-04-16) column 16, line 47 -column 17, line 75; examples ----	1,9-12
A	DE 38 20 775 A (THOMAE GMBH DR K) 21 December 1989 (1989-12-21) cited in the application claims 1,7-10 ----	1,9-12
A	US 3 940 395 A (SANTILLI ARTHUR A ET AL) 24 February 1976 (1976-02-24) column 3, line 22 - line 29; example XII ----	1,9-12
A	US 3 876 636 A (FAURAN CLAUDE P ET AL) 8 April 1975 (1975-04-08) column 7, line 18 -column 8, line 19; tables ----	1,9-12
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

11 December 2001

Date of mailing of the international search report

02/01/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Hass, C

INTERNATIONAL SEARCH REPORT

Inte	nal Application No
PCT/EP 01/08186	

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CHEMICAL ABSTRACTS, vol. 105, no. 5, 4 August 1986 (1986-08-04) Columbus, Ohio, US; abstract no. 42679v, page 727; XP002185307 abstract & D FREHEL ET AL: J. HETEROCYCL. CHEM., vol. 22, no. 4, 1985, pages 1011-16, -----	1
A	CHEMICAL ABSTRACTS, vol. 74, no. 25, 21 June 1971 (1971-06-21) Columbus, Ohio, US; abstract no. 141677r, page 582; XP002185308 abstract & H YAMAMOTO ET AL: BULL. CHEM. SOC. JAP., vol. 44, no. 1, 1971, pages 153-8, -----	1
A	WO 92 07844 A (PFIZER) 14 May 1992 (1992-05-14) page 64, line 8 - line 10; claim 1; examples 126,127,133,134 -----	1
A	EP 0 274 324 A (SANOFI SA) 13 July 1988 (1988-07-13) cited in the application -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte
n
onal Application No

PCT/EP 01/08186

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 3804849	A 16-04-1974	DE 2040510 A1		17-02-1972
		DE 2127267 A1		14-12-1972
		AT 310174 B		15-08-1973
		AT 310179 B		15-08-1973
		AT 310180 B		15-08-1973
		AT 310181 B		15-08-1973
		AT 310764 B		15-09-1973
		AT 310182 B		15-08-1973
		AU 462319 B		19-06-1975
		AU 3241171 A		22-02-1973
		BE 771330 A1		14-02-1972
		BG 17968 A3		05-03-1974
		BG 17785 A3		25-12-1973
		BG 17786 A3		25-12-1973
		CA 965423 A1		01-04-1975
		CH 561730 A5		15-05-1975
		CH 562829 A5		13-06-1975
		CH 571009 A5		31-12-1975
		CH 562830 A5		13-06-1975
		CH 571003 A5		31-12-1975
		CS 178084 B2		31-08-1977
		DK 136654 B		07-11-1977
		ES 393881 A1		16-09-1973
		ES 396451 A1		16-05-1974
		ES 396452 A1		16-05-1974
		ES 396453 A1		16-05-1974
		ES 396454 A1		16-05-1974
		FI 54925 B		29-12-1978
		FR 2102192 A5		07-04-1972
		GB 1321509 A		27-06-1973
		HU 162343 B		29-01-1973
		IE 35517 B1		03-03-1976
		IL 37492 A		14-03-1974
		JP 52046236 B		22-11-1977
		NL 7111176 A ,B,		16-02-1972
		NO 131887 B		12-05-1975
		RO 60635 A1		15-10-1976
		RO 59127 A1		15-02-1976
		RO 59322 A1		15-02-1976
		RO 59129 A1		15-01-1976
		RO 59925 A1		15-08-1976
		SE 380529 B		10-11-1975
		SU 442601 A3		05-09-1974
		SU 461507 A3		25-02-1975
		SU 503526 A3		15-02-1976
		SU 461508 A3		25-02-1975
		SU 474151 A3		14-06-1975
		US 3907996 A		23-09-1975
		YU 208471 A ,B		31-12-1979
		YU 288178 A ,B		31-12-1979
DE 3820775	A 21-12-1989	DE 3820775 A1		21-12-1989
		AT 106082 T		15-06-1994
		AU 617188 B2		21-11-1991
		AU 3659389 A		21-12-1989
		CA 1337195 A1		03-10-1995
		DD 284021 A5		31-10-1990
		DE 58907706 D1		30-06-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte
rnal Application No

PCT/EP 01/08186

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 3820775	A	DK	301689 A	21-12-1989
		EP	0347766 A2	27-12-1989
		ES	2057022 T3	16-10-1994
		FI	892991 A , B,	21-12-1989
		HU	51630 A2	28-05-1990
		IE	64661 B1	23-08-1995
		IL	90650 A	13-05-1993
		JP	2045489 A	15-02-1990
		JP	2776892 B2	16-07-1998
		KR	130202 B1	09-04-1998
		NO	176357 B	12-12-1994
		NZ	229637 A	29-01-1991
		PT	90907 A , B	29-12-1989
		SU	1731061 A3	30-04-1992
		US	5068325 A	26-11-1991
		ZA	8904636 A	27-02-1991
US 3940395	A	24-02-1976	NONE	
US 3876636	A	08-04-1975	FR 2158081 A1	15-06-1973
			AU 465951 B	09-10-1975
			AU 4811072 A	26-04-1974
			BE 790287 A1	19-04-1973
			CA 980775 A1	30-12-1975
			CH 551418 A	15-07-1974
			DE 2252822 A1	03-05-1973
			ES 407913 A1	16-11-1975
			FR 2225154 A2	08-11-1974
			GB 1339389 A	05-12-1973
			JP 927609 C	13-10-1978
			JP 49005979 A	19-01-1974
			JP 53005677 B	01-03-1978
			LU 66378 A1	03-05-1973
			NL 7214533 A	02-05-1973
			SE 398349 B	19-12-1977
			SU 490290 A3	30-10-1975
			ZA 7207579 A	25-07-1973
WO 9207844	A	14-05-1992	AT 124694 T	15-07-1995
			AU 644035 B2	02-12-1993
			AU 9059291 A	26-05-1992
			BR 9107070 A	31-05-1994
			CA 2095213 A1	07-05-1992
			CN 1061411 A	27-05-1992
			CZ 9204009 A3	15-12-1993
			DE 9190155 U1	07-10-1993
			DE 69111077 D1	10-08-1995
			DE 69111077 T2	02-11-1995
			DK 556310 T3	21-08-1995
			EP 0556310 A1	25-08-1993
			ES 2074867 T3	16-09-1995
			FI 932032 A	05-05-1993
			GR 3017122 T3	30-11-1995
			HU 64533 A2	28-01-1994
			IE 913854 A1	22-05-1992
			MX 9101913 A1	08-07-1992
			NO 931635 A	05-05-1993
			NZ 240476 A	27-04-1994

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/08186

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9207844	A	PT	99415 A	30-09-1992
		SK	400992 A3	09-08-1995
		US	5444062 A	22-08-1995
		WO	9207844 A1	14-05-1992
		ZA	9108767 A	05-05-1993
<hr/>				
EP 0274324	A	FR	2608607 A1	24-06-1988
		AT	60768 T	15-02-1991
		AU	602036 B2	27-09-1990
		AU	8252787 A	23-06-1988
		CA	1308729 A1	13-10-1992
		DE	3767993 D1	14-03-1991
		EP	0274324 A1	13-07-1988
		FI	875596 A ,B,	24-06-1988
		GR	3001816 T3	23-11-1992
		HU	48616 A2	28-06-1989
		IE	60381 B	13-07-1994
		JP	2113339 C	21-11-1996
		JP	8032702 B	29-03-1996
		JP	63166875 A	11-07-1988
		PT	86375 A ,B	01-01-1988
		US	4876362 A	24-10-1989
<hr/>				